Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of “Moderate Buy” by Analysts

Arvinas, Inc. (NASDAQ:ARVN) has been given an average rating of “Moderate Buy” by the thirteen brokerages that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $56.08.

Several equities research analysts have commented on the stock. Stifel Nicolaus decreased their price objective on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Guggenheim reiterated a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. Oppenheimer lowered shares of Arvinas from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Citigroup decreased their price objective on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, March 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th.

Arvinas Stock Performance

Shares of NASDAQ ARVN opened at $8.30 on Wednesday. Arvinas has a fifty-two week low of $7.91 and a fifty-two week high of $46.62. The stock has a market cap of $570.81 million, a price-to-earnings ratio of -3.00 and a beta of 1.95. The firm’s 50-day simple moving average is $18.19 and its 200 day simple moving average is $22.33.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the business posted ($2.53) EPS. On average, sell-side analysts predict that Arvinas will post -3.81 EPS for the current year.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,572 shares of company stock worth $695,030. Corporate insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Arvinas

A number of hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. bought a new stake in Arvinas during the 4th quarter valued at $28,000. KBC Group NV raised its holdings in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares during the last quarter. Quantbot Technologies LP increased its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Arvinas during the 4th quarter valued at $171,000. Finally, Tema Etfs LLC purchased a new position in Arvinas during the 4th quarter valued at $227,000. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.